UFPT vs ITGR vs NVCR vs PFBC vs ABT

For growth investors, UFP Technologies, Inc.

(UFPT) is the stronger pick with 19. 5% revenue growth year-over-year, versus -4. 1% for Preferred Bank (PFBC). Preferred Bank (PFBC) offers the better valuation at 9. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate UFP Technologies, Inc. (UFPT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Preferred Bank (PFBC) is the cheapest at 9.

1x versus Integer Holdings Corporation at 30. 4x. On forward P/E, Preferred Bank is actually cheaper at 8. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Preferred Bank wins at 0. 51x versus Integer Holdings Corporation's 3. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, UFP Technologies, Inc.

(UFPT) delivered a total return of +306. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: UFPT returned +785. 4% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 788% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), UFP Technologies, Inc.

(UFPT) is pulling ahead at 19. 5% versus -4. 1% for Preferred Bank (PFBC). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -15. 0% for Integer Holdings Corporation. Over a 3-year CAGR, UFPT leads at 19. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFBC leads at 38. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Preferred Bank (PFBC) is the more undervalued stock at a PEG of 0. 51x versus Integer Holdings Corporation's 3. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Preferred Bank (PFBC) trades at 8. 9x forward P/E versus 23. 3x for UFP Technologies, Inc. — 14. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, PFBC (3.

1% yield), ABT (2. 5% yield) pay a dividend. UFPT, ITGR, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (UFPT (Healthcare) and ITGR (Healthcare) and NVCR (Healthcare) and PFBC (Financial Services) and ABT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: UFPT is a small-cap high-growth stock; ITGR is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; PFBC is a small-cap deep-value stock; ABT is a mid-cap deep-value stock. PFBC, ABT pay a dividend while UFPT, ITGR, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.